AstraZeneca announced Tuesday that it will cease discovery research in 10 of its current disease areas, and close sites in Europe and the US, which will eliminate about 1800 jobs. The move is part of the drugmaker's previously announced plans to cut 8000 jobs.

The drugmaker will halt R&D in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression and anxiety, hepatitis C and vaccines other than respiratory syncytial virus and influenza.

Anders Ekblom, head of development, noted that "We have made real strides in improving our efficiency in recent years, but there is a continuing need to adapt our organisation in anticipation of future challenges."

Early-stage discovery research will stop at the company's facility in Wilmington, Delaware, which will affect about 550 jobs. In the UK, the drugmaker will close its Charnwood research centre with a loss of up to 1200 jobs, although some of these employees will be offered the chance to transfer to other areas of the company. A smaller site in Cambridge will also be shuttered.

In Sweden, AstraZeneca will close its research site in Lund and increase the work force at its Molndal facility to accommodate activities to be transferred from other sites. The company reported that it will also consider divesting its antiviral unit Arrow Therapeutics, which it bought in 2007.

المفضلة

إرسال إلى صديق

التعليقات (0)

أضف تعليق

الإسم

البريد الإلكتروني

العنوان

التعليق

تصغير | تكبير

أضف تعليق